BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 37138160)

  • 1. Fluid and Biopsy Based Biomarkers in Parkinson's Disease.
    Coughlin DG; Irwin DJ
    Neurotherapeutics; 2023 Jul; 20(4):932-954. PubMed ID: 37138160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of alpha-synuclein aggregates in gastrointestinal biopsies by protein misfolding cyclic amplification.
    Fenyi A; Leclair-Visonneau L; Clairembault T; Coron E; Neunlist M; Melki R; Derkinderen P; Bousset L
    Neurobiol Dis; 2019 Sep; 129():38-43. PubMed ID: 31078683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The promise of amplification assays for accurate early detection of α-synucleinopathies: A review.
    Kurapova R; Chouliaras L; O'Brien JT
    Exp Gerontol; 2022 Aug; 165():111842. PubMed ID: 35623540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropathology and molecular diagnosis of Synucleinopathies.
    Koga S; Sekiya H; Kondru N; Ross OA; Dickson DW
    Mol Neurodegener; 2021 Dec; 16(1):83. PubMed ID: 34922583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct tau and alpha-synuclein molecular signatures in Alzheimer's disease with and without Lewy bodies and Parkinson's disease with dementia.
    van der Gaag BL; Deshayes NAC; Breve JJP; Bol JGJM; Jonker AJ; Hoozemans JJM; Courade JP; van de Berg WDJ
    Acta Neuropathol; 2024 Jan; 147(1):14. PubMed ID: 38198008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson's disease and dementia with Lewy bodies.
    Bargar C; Wang W; Gunzler SA; LeFevre A; Wang Z; Lerner AJ; Singh N; Tatsuoka C; Appleby B; Zhu X; Xu R; Haroutunian V; Zou WQ; Ma J; Chen SG
    Acta Neuropathol Commun; 2021 Apr; 9(1):62. PubMed ID: 33827706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of alpha-synuclein conformational variants from gastro-intestinal biopsy tissue as a potential biomarker for Parkinson's disease.
    Ruffmann C; Bengoa-Vergniory N; Poggiolini I; Ritchie D; Hu MT; Alegre-Abarrategui J; Parkkinen L
    Neuropathol Appl Neurobiol; 2018 Dec; 44(7):722-736. PubMed ID: 29676021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RT-QuIC and Related Assays for Detecting and Quantifying Prion-like Pathological Seeds of α-Synuclein.
    Srivastava A; Alam P; Caughey B
    Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological α-synuclein detected by real-time quaking-induced conversion in synucleinopathies.
    Huang J; Yuan X; Chen L; Hu B; Wang H; Wang Y; Huang W
    Exp Gerontol; 2024 Mar; 187():112366. PubMed ID: 38280659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder.
    Stefani A; Iranzo A; Holzknecht E; Perra D; Bongianni M; Gaig C; Heim B; Serradell M; Sacchetto L; Garrido A; Capaldi S; Sánchez-Gómez A; Cecchini MP; Mariotto S; Ferrari S; Fiorini M; Schmutzhard J; Cocchiara P; Vilaseca I; Brozzetti L; Monaco S; Jose Marti M; Seppi K; Tolosa E; Santamaria J; Högl B; Poewe W; Zanusso G;
    Brain; 2021 May; 144(4):1118-1126. PubMed ID: 33855335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrasensitive Detection of Aggregated α-Synuclein in Glial Cells, Human Cerebrospinal Fluid, and Brain Tissue Using the RT-QuIC Assay: New High-Throughput Neuroimmune Biomarker Assay for Parkinsonian Disorders.
    Manne S; Kondru N; Hepker M; Jin H; Anantharam V; Lewis M; Huang X; Kanthasamy A; Kanthasamy AG
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):423-435. PubMed ID: 30706414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson's disease patients.
    Manne S; Kondru N; Jin H; Anantharam V; Huang X; Kanthasamy A; Kanthasamy AG
    Mov Disord; 2020 Feb; 35(2):268-278. PubMed ID: 31758740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's and Lewy body dementia CSF biomarkers.
    Parnetti L; Paciotti S; Farotti L; Bellomo G; Sepe FN; Eusebi P
    Clin Chim Acta; 2019 Aug; 495():318-325. PubMed ID: 31051162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders.
    Altay MF; Liu AKL; Holton JL; Parkkinen L; Lashuel HA
    Acta Neuropathol Commun; 2022 Nov; 10(1):163. PubMed ID: 36371251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson's disease and dementia with Lewy bodies.
    Brockmann K; Quadalti C; Lerche S; Rossi M; Wurster I; Baiardi S; Roeben B; Mammana A; Zimmermann M; Hauser AK; Deuschle C; Schulte C; Waniek K; Lachmann I; Sjödin S; Brinkmalm A; Blennow K; Zetterberg H; Gasser T; Parchi P
    Acta Neuropathol Commun; 2021 Oct; 9(1):175. PubMed ID: 34717775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
    Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease.
    Wang Z; Becker K; Donadio V; Siedlak S; Yuan J; Rezaee M; Incensi A; Kuzkina A; Orrú CD; Tatsuoka C; Liguori R; Gunzler SA; Caughey B; Jimenez-Capdeville ME; Zhu X; Doppler K; Cui L; Chen SG; Ma J; Zou WQ
    JAMA Neurol; 2020 Sep; 78(1):1-11. PubMed ID: 32986090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
    Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
    Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies.
    Muntané G; Dalfó E; Martinez A; Ferrer I
    Neuroscience; 2008 Apr; 152(4):913-23. PubMed ID: 18343584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.